Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: David Cathcart who wrote (145)	10/22/1998 9:46:00 AM
From: scaram(o)uche	Respond to of 1073

>> Am I seeing significance that is not there in the efficacy results revealed in the high dose patients in the phase I trial? Particularly in the case of the pancreatic patient. << One patient is an observation, not "data". ;-) We'll see, David. Going over the old argument with Miljenko and me won't do any good. Blitzer didn't deliver under either scenario. That doesn't mean that it's not good for shareholders. I just prefer to distribute risk. Yes, the data that Richard summarized makes MOGN a potential big-time winner, and the more clinical data that it collected, the more leveraged is the business plan. Rick